Pre-Exposure Prophylaxis and Adolescent Girls and Young Women in Eastern and Southern Africa: The latest insights

16 July 2024

Eastern and southern Africa (ESA) is the world’s most heavily HIV-impacted region, with adolescent girls and young women (AGYW) disproportionately affected. To support the scale-up of PrEP amongst AGYW in ESA, in September 2021 UNICEF and partners released the implementation brief “Improving the Quality of Pre-Exposure Prophylaxis Implementation for Adolescent Girls and Young Women in Eastern and Southern Africa,” highlighting considerations to help improve the quality and coverage of AGYW PrEP programming.

The PrEP landscape has evolved significantly in the three years since the original brief was released, both in scale and variety. This updated brief summarises the most recent evidence on AGYW PrEP provision, serving as a supplement to the original 2021 implementation brief.

Featured Resources

Document

CAB PrEP Introduction Supply Chain Considerations – Kenya 2023

This document summarizes considerations for the integration of CAB PrEP within Kenya’s supply chain system based on interview with key national and subnational stakeholders.

External Link

WHO Implementation Tool for Pre-Exposure Prophylaxis (PrEP) of HIV Infection

The WHO has developed this series of modules to support the implementation of PrEP among a range of populations in different settings.

Presentation

Leading the Way: Early learnings from CAB for PrEP introduction in Zambia and Zimbabwe

Programmatic rollout of long-acting injectable cabotegravir (CAB for PrEP) has launched in Zambia and Zimbabwe! Recommended by the World Health Organization as a safe and effective HIV prevention method in 2022, these two countries are now the first in Africa to incorporate this new, long-awaited PrEP product into their national HIV prevention programs. In the…

Document

The Lens on LEN

In late June 2024, Gilead Sciences announced an early review of the data of the PURPOSE 1 trial by an independent monitoring board, which found that injectable lenacapavir (LEN) provided as prevention was safe and highly effective against HIV. The product is being tested among 5,300 HIV-negative cisgender women ages 16-25 in Uganda and South…

External Link

Low Selection of HIV PrEP Refills at Private Pharmacies among Clients who Initiated PrEP at Public Clinics: Findings from a mixed-methods study in Kenya

This article from BMC Health Services Research describes the impact of a pilot project to permit oral PrEP users to obtain refills at private pharmacies for an additional fee.

External Link

Frontiers in Reproductive Health Special Issue: Multipurpose Prevention Technologies

This special issue of Frontiers in Reproductive Health contains the latest research and insights on Multipurpose Prevention Technologies (MPTs), products designed to address two or more health concerns, including prevention of HIV, sexually transmitted infections, and pregnancy. Articles include: Editorial: Multipurpose prevention technologies for HIV, STIs and pregnancies Turning the promise of multipurpose prevention technologies…

Presentation

Nigeria National Oral PrEP Implementation Plan (2022-24) Assessment Presentation

From October 2023 to April 2024, MOSAIC supported the Federal Ministry of Health to evaluate the National Oral PrEP Implementation Plan (Jan 2022 – Jan 2024). The purpose of the evaluation was to assess the achievement of priority activities stipulated in the National Oral PrEP Implementation Plan (Jan 2022-Jan 2024) against the intended objectives. The…

Document

Nigeria National Oral PrEP Implementation Plan (2022-24) Assessment Report

Spreadsheet

Access Workbook for Cabotegravir for PrEP and Dapivirine Vaginal Ring

This workbook, compiled by the Global Fund, contains key access information relating to cabotegravir (CAB) for PrEP and the dapivirine vaginal ring (DVR) for all lower and middle income countries, including eligibility for Global Fund support, PEPFAR support status, regulatory status of CAB for PrEP and the DVR, access to non-profit product pricing, and information…

Presentation

Generic CAB for PrEP Development and Access

This presentation from Medicines Patent Pool explains the process of licensing, developing, and manufacturing generic cabotegravir (CAB) for PrEP, including expected timelines for generic CAB for PrEP availability.